For the millions living with Long COVID and ME/CFS — conditions notoriously resistant to conventional rehabilitation — even a compelling anecdote about complete symptom resolution warrants careful scrutiny. The challenge is particularly acute because post-exertional malaise renders standard exercise-based therapies potentially harmful, leaving clinicians with few evidence-backed tools.
This case report documents a 41-year-old woman who developed severe, refractory Long COVID symptoms following SARS-CoV-2 infection, including profound fatigue (VAS 79/100), bilateral upper extremity numbness, brain fog, and insomnia — meeting full diagnostic criteria for ME/CFS. After prior trials of sertraline (titrated to 50 mg/day) and other symptomatic medications yielded no meaningful improvement, she underwent kanshoho — a low-pressure manual muscle relaxation technique — administered across 10 sessions over approximately 2.5 months, alongside activity pacing guidance. At final assessment, fatigue VAS dropped from 79 mm to 0 mm, performance status normalized from 7 to 0, and total mood disturbance scores shifted from 136 to -19 on the Profile of Mood States, Second Edition. Sertraline was eventually tapered and discontinued without apparent symptom recurrence.
The honest interpretation here requires discipline. A single case report cannot establish causality — natural disease fluctuation, concurrent pacing advice, placebo response, and the tapering of sertraline (which can itself cause fatigue) are all plausible contributors to improvement. Kanshoho is virtually unstudied in peer-reviewed literature outside Japan, making mechanism speculation premature. ME/CFS research has a troubled history with manual and behavioral interventions that later failed replication in controlled trials. What this report does usefully contribute is a signal worth investigating: a non-exertional, low-risk manual therapy that, if it avoids triggering post-exertional malaise, could theoretically occupy a niche currently empty of safe options. A randomized controlled trial with validated ME/CFS outcome measures would be the necessary next step before any population-level inference is appropriate.
